Begin main content

Hemlibra (Emicizumab): Economic Review Report

Last updated: September 11, 2019
Project Number: OB0005-000
Product Line: Technology Review
Research Type: Drug
Result type: Report

This report aims to:

  • Assess the cost effectiveness of emicizumab (Hemlibra) used as prophylaxis compared with prophylaxis with bypassing agents (BPA) and on-demand (episodic) use of BPAs, in patients hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
  • Assess, from the Canadian health ministry perspective, the budgetary impact of reimbursing emicizumab, over a three-year period, in patients hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.